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ANONYMOUS TITLE PAGE 1 
 2 
Quality of Life in Individuals with Patellofemoral Pain: A Systematic Review Including 3 
Meta-analysis. 4 
 5 
 6 
  7 
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ABSTRACT 8 
Objective: The aim of this systematic review is to describe QoL in individuals with PFP, and 9 
determine the impact of PFP interventions on QoL. 10 
Methods: Five databases were searched for studies reporting QoL in individuals with PFP, 11 
with mean age under 50 years. Data were pooled based on QoL tool (e.g. Knee Injury and 12 
Osteoarthritis Outcome Score [KOOS] QoL subscale, Short-Form 36 item health survey [SF-13 
36]) using random-effects models, or through narrative synthesis where inadequate data were 14 
available. 15 
Results: Individuals with PFP, had worse KOOS-QOL scores (pooled mean: 47[95% CI: 34 16 
to 61] and health-related QoL (pooled SF-36 PCS and MCS: 47[95% CI: 41 to 53] and 17 
54[95% CI: 47 to 62], respectively) compared with pain-free controls and population norms. 18 
Physical interventions were associated with improvements in knee- and health- related QoL 19 
in individuals with PFP in repeated measures studies. However, the effect of physical 20 
interventions compared to a control treatment was confli ting. 21 
Conclusion: Individuals with PFP aged under 50 years, have markedly reduced knee- and 22 
health-related QoL compared to pain-free controls and population norms. Knee- and health-23 
related QoL may improve following intervention, but it is unclear if these improvements are 24 
greater than that which occur in a control group. 25 
Keywords: anterior knee pain, patellofemoral pain syndrome, KOOS, SF-36, intervention 26 
 27 
1. INTRODUCTION 28 
Patellofemoral pain (PFP) is a common disorder of the knee,55 prevalent in adolescent31 and 29 
adult populations,62 and particularly prevalent in physically active individuals.35 PFP is a 30 
chronic, painful condition predominantly of insidious onset, which often persists despite 31 
provision of evidence-based treatments.37 Research suggests that 57% of individuals with 32 
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PFP may experience persistent symptoms and unfavourble outcomes 5-8 years after 33 
enrolment in a clinical trial.28 Moreover, symptom severity may remain unchanged or 34 
progress in 50% of affected individuals,7 often restricting an individual’s participation in35 
physical activity40 and potentially reducing quality of life (QoL).  36 
 37 
Health-related QoL is a multi-dimensional concept, encompassing physical, psychological 38 
and social aspects associated with a disease or itstreatment.19 Disease-specific and generic 39 
health-related QoL measures are used to evaluate pati nt experience of a musculoskeletal 40 
condition and the benefit of therapeutic interventio s.46 The patients’ perspective and 41 
experience should be paramount when evaluating the impact of a condition or the efficacy of 42 
an intervention.45 The use of QoL instruments recognizes that patient p rceptions do not 43 
always match with knee pathology50 or findings from a clinical examination of the knee.24 44 
Although rarely the primary outcome of interest, knee- and health- related QoL outcomes 45 
have been reported in a number of studies investigating individuals with PFP, and have been 46 
used to evaluate intervention efficacy for this condition. Synthesis of this evidence will 47 
provide a better understanding of the impact of PFP and the influence of specific treatment 48 
strategies on QoL. 49 
 50 
This systematic review aims to: (i) describe QoL in individuals with PFP compared to pain-51 
free controls and population norms; (2) evaluate whether intervention is associated with 52 
improved QoL in individuals with PFP; and (3) identify factors associated with QoL in 53 
individuals with PFP. 54 
 55 
2. METHODS 56 
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This systematic review followed the Preferred Reporting Items for Systematic reviews and 57 
Meta-Analysis (PRISMA) guidelines,30 with the protocol prospectively registered on 58 
PROSPERO (http://www.crd.york.ac.uk/PROSPERO/; CRD 42016026307, 12 April 2016). 59 
There were no peer-reviewed literature reviews of this topic at the time. 60 
 61 
2.1 Literature Search Strategy 62 
A comprehensive search strategy was devised for the following electronic databases: (i) 63 
AMED, (ii) CINAHL via EBSCO, (iii) Cochrane Central Register of Controlled Trials, (iv) 64 
EMBASE via OVID, and (v) MEDLINE via OVID. Diagnostic search terms from a 65 
Cochrane systematic review of exercise interventions f r individuals with PFP were used to 66 
identify PFP literature;54 and combined with terms for QoL measurement tools, similar to the 67 
strategy used by Filbay et al, 2014.17 The search strategy for MEDLINE is presented in 68 
Appendix 1, and was adjusted to suit other databases. All potentially eligible papers were 69 
imported into EndNote X7.2.1 (Thomson Reuters, Carlsb d, California, USA) and duplicates 70 
were removed. The search was conducted in April, 2016. Two reviewers (X and Y) 71 
independently screened the titles and abstracts of all articles using a checklist based on the 72 
eligibility criteria. Papers with insufficient information in title and abstract to determine 73 
eligibility were retained for full-text evaluation using the same checklist. Reference lists of all 74 
publications considered for inclusion were hand-searched and citation tracking was 75 
completed using Google Scholar. The final lists of eligible articles were compared between 76 
the two reviewers, with a third reviewer available to resolve any disagreement (Z).  77 
 78 
2.2 Selection Criteria 79 
All studies reporting QoL in individuals with PFP were included, regardless of study design 80 
methodology. Participants in the studies were requir d to be experiencing PFP/retropatellar 81 
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knee pain/anterior knee pain or be diagnosed with chondromalacia patella. Studies were 82 
excluded if participants had other knee conditions (such as a ligament or meniscal injury, 83 
patellar tendinopathy, recurrent patella subluxation, diagnosed radiographic osteoarthritis or 84 
were preoperative patients awaiting surgery for their PFP). No other treatment intervention 85 
was excluded. To reduce the likelihood that a propotion of study participants may have 86 
undiagnosed patellofemoral osteoarthritis (PFOA) studies of participants with mean age of 87 
greater than 50 years were excluded from this systematic review.21 Studies not published in 88 
English, French, German or Danish were ineligible. In the case of multiple studies using the 89 
same cohort, the study reporting QoL outcomes for the largest sample size was included.  90 
 91 
2.3 Assessment of Reported Methodological Quality  92 
Two independent reviewers (X, W) rated the reported methodological quality of included 93 
studies using two separate scales. The first scale w s a checklist adapted from the 21-item 94 
Downs and Black checklist which is suitable for randomised and non-randomised studies 95 
(Appendix 2)15. Items were scored according to the method used by Downs and Black (1998): 96 
‘Yes’ (score=1), ‘No’ (score=0), or ‘Not Applicable’ (items removed from scoring), except 97 
for Item 5 (i.e. description of principle confounders clearly described) which was scored 98 
‘Yes’ (score=2), ‘Partially’ (score=1) or ‘No’ (score=0). Items considered not applicable to 99 
assess intervention studies were removed, resulting in a modified checklist of 15 items. One 100 
of the 15 items, concerning follow-up, was not applicable to cross-sectional studies and 6 101 
items were not applicable to validity and reliability studies so were removed from scoring, 102 
leaving 14 and 8 items, respectively. Therefore a percentage score was calculated from 103 
relevant items for the three different study design. The median value was identified to assign 104 
a level of methodological quality. Studies were classified as higher reported quality (study 105 
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score equal to or greater than the median value) and lower reported quality (study score less 106 
than the median value).38  107 
 108 
The second scale used was The Cochrane Risk of Bias Tool.22 This tool is specifically used 109 
for controlled intervention studies to provide explicit assessment of each component risk of 110 
bias.58 The additional quality assessment tool provided more comprehensive evaluation of 111 
intervention study outcomes to inform the second aim of this review. The Cochrane Risk of 112 
Bias Tool is comprised of a 7 domain checklist to assess selection bias (2 domains), 113 
performance bias (1 domain), detection bias (1 domain), ttrition bias (1 domain), reporting 114 
bias (1 domain), and other bias (1 domain). Domains were recorded as low or high risk of 115 
bias or risk of bias unclear. Risk of bias within studies was summarised as low risk (low risk 116 
of bias for all domains), unclear risk (low or unclear risk of bias for all domains), or high risk 117 
(high risk of bias for one or more domain).22 Any inter-rater disagreement was discussed in a 118 
consensus meeting and unresolved items were taken to a third reviewer (Z) for consensus. A 119 
level of evidence was assigned for intervention study data using the statistical outcomes and 120 
methodological quality of included studies, based on recommendations by van Tulder.56 121 
 122 
2.4 Data Management and Statistical Analyses 123 
Participant (e.g. sex, age, BMI) and study (e.g. study design) characteristics, QoL, and type of 124 
treatment for intervention studies, were independently extracted (X). If sufficient data were 125 
not reported in the published article or supplementary material provided, the corresponding 126 
author was contacted to request further information. Data were cross-checked by a second 127 
reviewer (V). When intervention studies reported QoL data at multiple time points post-128 
treatment for PFP, data from the first follow-up after treatment were extracted. If BMI data 129 
were not reported, then it was estimated from mean height and mass data. 130 
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 131 
Normative QoL data were obtained from previously published population studies. Studies 132 
with QoL data available from the largest number of participants of a comparable age were 133 
selected.9,23,29,33 Pain-free control data were obtained from included stu ies.5,36,39,42 134 
 135 
Data were analyzed based on QoL instrument. Knee-related QoL was measured with the 136 
Knee injury and Osteoarthritis Outcome Score QoL subscale (KOOS-QoL). Health-related 137 
QoL was measured with: i) the 36-Item Short Form Survey (SF-36) reported as 8 domain 138 
scores and/or physical and mental component summary scores (PCS and MCS respectively), 139 
(ii) the 8-Item Short Form Survey (SF-8) reported as 8 domain scores, or (iii) the European 140 
QoL-5 Dimension (EQ-5D) index score. To address the first aim of this review, pooled mean 141 
[95% CI] QoL data from individuals with PFP, pain-free controls, and normative populations 142 
are presented. Baseline mean QoL scores from intervention studies were pooled with QoL 143 
data from all other studies. To address the second aim of this review, random effects meta-144 
analyses were used to compare QoL between pre- and post-treatment for repeated measure 145 
design intervention studies and to compare QoL outcomes between treatment and control 146 
groups for controlled intervention studies (Review Manager Version 5.3). Pooled findings of 147 
intervention studies were considered heterogeneous if I 2 >50%  was statistically significant 148 
(p<0.05). Standardized mean differences (SMD) [95% CI] are reported. The magnitude of the 149 
pooled SMD was interpreted based on Cohen’s criteria, where SMD ≥0.8 was interpreted as a 150 
large effect, >0.5 and <0.8 a moderate effect, and >0.2 and <0.5 a small effect.18  151 
 152 
2.5 Deviations from study protocol 153 
Initially, we were interested in exploring the association between secondary outcomes (i.e. 154 
body mass index [BMI], age, pain) and QoL through a meta-regression analysis (ie. Aim 3). 155 
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However, due to a low number of included case-control studies for each QoL instrument, a 156 
meta-analysis comparing QoL and secondary outcomes was not possible. Considering at least 157 
10 studies should be included in a meta-analysis for each covariate in order for a meta-158 
regression analysis to be meaningful, it was not possible to conduct the planned meta-159 
regression analysis8. Additionally, the Cochrane risk of bias tool22 was added to enhance 160 
examination of the risk of bias of included randomized controlled trials (RCT). 161 
 162 
3.0 RESULTS 163 
3.1 Search Strategy, Methodological Quality, and Risk of Bias 164 
The comprehensive search strategy identified 1573 titles, with 1304 titles and abstracts 165 
evaluated after removal of duplicates. The full-text of 93 articles were retrieved and assessed 166 
for eligibility. Two additional papers were identified by citation tracking, and four were 167 
identified in an updated search performed prior to final data analysis using the same search 168 
strategy, in January, 2017. Twenty-one studies met the selection criteria (Figure 1).  169 
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 170 
Thirteen authors (for 15 studies) were contacted to ob ain raw data, 10 responded and of 171 
these, 8 supplied data for 9 studies4,11,14,32,34,36,41,47,57. QoL data were extracted for 1111 172 
individuals with PFP and 100 pain-free controls. Characteristics of included studies are 173 
presented in Table 1. 174 
 175 
 176 
 177 
 178 
 179 
 180 
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TABLE 1: Characteristics of the included studies. 181 
  
Study PFP participants 
 
Control  
participants 
 
Aim/Comparison/ 
Intervention 
Rx 
Duration 
QOL 
measure(s) 
Domain PFP Comparator 
 
Cross-sectional         
Assa 2015 
(Israel) 
n = 157 
Age = 30 (5) 
BMI = 24 (3) 
W = 42% 
n = 31, Pain-free 
Age = 32 (4) 
BMI = 23 (3) 
W = 45% 
 
PFP compared to 
control  
 SF-36 
 
PF  
RP  
BP  
GH  
V    
SF  
RE 
MH 
PCS 
MCS 
65 [62 to 68] 
40 [34 to 45] 
50 [47 to 54] 
65 [62 to 68] 
54 [51 to 57] 
77 [73 to 80] 
65 [58 to 71] 
69 [67 to 72] 
55 [52 to 57] 
66 [63 to 69] 
97 [96 to 99] 
97 [93 to101] 
92 [88 to 96] 
82 [88 to 96] 
72 [67 to 75] 
97 [95 to 100] 
98 [95 to 101] 
79 [76 to 83] 
88 [86 to 90]  
86 [83 to 88] 
Rathleff CR 2013 
(Denmark) 
n = 20 
Age = 15 (1) 
BMI = 20 (3) 
W = 80% 
n = 20,  Healthy 
Age = 15 (1) 
BMI = 19 (1) 
W = 80% 
 
PFP compared to 
control 
 KOOS-QOL  
EQ-5D 
(index) 
 54 [49 to 60] 
0.72 [0.68 to 0.78] 
98 [95 to 101] 
1.0 [1.0 to 1.0] 
Rathleff MS 2013 
(Denmark) 
n = 57˄  
Age = 17 (1) 
BMI = 21 (2) 
W = 100% 
n = 29,  Pain-free 
Age = 17 (1) 
BMI = 21 (3) 
W = 100% 
 
PFP compared to 
control  
 KOOS-QOL  54† [50 to 58] 
 
99 [98 to 100] 
Rathleff MS 2016 
(Denmark) 
n = 20˄  
Age = 20 (20-21) 
BMI =22* (NR ) 
W = 100% 
n = 20,  Pain-free 
Age = 21 (19-21) 
BMI =22* (NR) 
W = 100% 
PFP compared to 
control 
 KOOS-QOL  55† [47 to 63] 97 [94 to 100] 
Study PFP 
 
Control 
 
Aim/Comparison/ 
Intervention 
Rx 
Duration 
QOL 
measures 
Domain PFP Comparator 
 
Cheung 2013 Amateur athletes   Amateur compared to  SF-36 PF 88 [80 to 96]  
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(China) n = 19 
Age = 23 (1) 
BMI = 20* (NR) 
W = NR 
 
 
professional athletes 
with PFP 
 RP 
BP 
GH 
V 
SF 
RE 
MH 
78 [59 to 96] 
63 [54 to 72] 
66 [56 to 74] 
63 [55 to 72] 
83 [72 to 93] 
67 [45 to 88] 
74 [66 to 81] 
 
  
Professional 
athletes  
n = 19 
Age = 21 (2) 
BMI = 20* (NR) 
W = NR 
 
    PF 
RP 
BP 
GH 
V 
SF 
RE 
MH 
75 [67 to 82] 
42 [23 to 61] 
51 [54 to 72] 
65 [56 to 74] 
55 [44 to 65] 
78 [71 to 86] 
58 [37 to 79] 
65 [58 to 71] 
 
Silva 2016 
(Brazil) 
Non-athletes 
n = 34 
Age = 15 (1) 
BMI = 22* (NR) 
W = 32% 
 
 Non-athletes compared 
to athletes with 
with PFP 
 KOOS-QOL  68 [62 to 74]  
 Athletes 
n = 22  
Age = 14 (1) 
BMI = 22 ( ) 
W = 36% 
     78 [70 to 86]  
Vincent 2010 
(Australia) 
n=33 
Age = NR 
BMI = NR 
W = NR 
 Knee pain (PFP 
subgroup obtained 
from author) 
 SF-8  
 
PF 
RP 
BP 
GH 
V 
SF 
49 [46 to 52] 
39 [36 to 42] 
35 [30 to 39] 
43 [41 to 46] 
51 [48 to 53] 
46 [43 to 49] 
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RE 51 [49 to 54] 
Study PFP 
 
Control 
 
Aim/Comparison/ 
Intervention 
Rx 
Duration 
QOL 
measures 
Domain PFP Comparator 
 
Vincent 2010 
(Australia) 
(Continued) 
n=33 
Age = NR 
BMI = NR 
W = NR 
 Knee pain (PFP 
subgroup obtained 
from author) 
 SF-8  
 
MH 
PCS 
MCS 
48 [46 to 51] 
40 [36 to 44] 
54 [51 to 57] 
 
Validity and reliability  
Apivatgaroon 2016 
(Thailand) 
n = 49 
Age = 47 (11) 
BMI = 25 (5) 
W = 80% 
 
 Testing validity & 
reliability of Kujala in 
PFP 
 SF-36 
 
PF 
RP 
BP 
GH 
V 
SF 
RE 
MH 
PCS 
MCS 
33 [26 to 39] 
54 [48 to 60] 
42 [37 to 47] 
47 [41 to 54] 
52 [47 to 57] 
54 [49 to 59] 
55 [49 to 62] 
59 [53 to 64] 
46 [41 to 50] 
53 [49 to 58] 
 
Cheung 2012 
(China) 
n = 64 
Age = 30 (6) 
BMI = 22* (NR) 
W = 41% 
 
 
 Testing validity & 
reliability 
Kujala in PFP 
 SF-36 
 
PF 
RP 
BP 
GH 
V 
SF 
RE 
MH 
88 [85 to 91] 
76 [68 to 84] 
58 [52 to 63] 
64 [60 to 69] 
62 [58 to 66] 
84 [79 to 89] 
79 [70 to 88] 
73 [69 to 76] 
 
Negahban 2013 
(Iran) 
n = 100 
Age = 25 (7) 
BMI = 23* (NR) 
W = 71% 
 Validity & reliability of 
Functional Index 
Questionnaire & 
Modified Functional 
Index Questionnaire in 
individuals with PFP 
 SF-36 
 
PF 
RP 
BP 
GH 
V 
SF 
RE 
65 [60 to 70] 
48 [40 to 55] 
51 [47 to 55] 
54 [50 to 57] 
58 [56 to 61] 
66 [62 to 70] 
45 [36 to 54] 
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MH 
PCS 
MCS 
64 [61 to 67] 
55 [52 to 58] 
58 [54 to 61] 
Study PFP 
 
Control 
 
Comparison or 
Intervention 
Rx 
Duration 
QOL 
measures 
Domain PFP Comparator 
 
Controlled intervention studies  
Crossley 2002 
(Australia) 
Treatment 
n = 36 
Age = 29 (8) 
BMI = 24 (4) 
W = 64% 
 
 Randomized controlled 
trial comparing change 
in QOL after active 
MMP in PFP vs. 
change after placebo 
intervention in PFP  
6 weeks SF-36 
 
PF 
RP 
BP 
GH 
V 
SF 
RE 
MH 
64 [57 to 71] 
59 [47 to 72] 
52 [45 to 59] 
71 [64 to 76] 
55 [49 to 61] 
67 [60 to74] 
81 [69 to 93] 
72 [67 to 77] 
79 [73 to 85] 
80 [70 to 91] 
77 [71 to 83] 
78 [72 to 84] 
64 [58 to 70] 
75 [69 to 81] 
85 [75 to 95] 
82 [78 to 86] 
 
  Placebo 
N = 34 
Age = 26 (8) 
BMI = 25 (4) 
W = 66% 
 
 6 weeks  PF 
RP 
BP 
GH 
V 
SF 
RE 
MH 
64 [58 to 70] 
57 [40 to 68] 
52 [44 to 58] 
71 [64 to 78] 
56 [51 to 63] 
69 [63 to 76] 
73 [60 to 86] 
75 [70 to 81] 
82 [78 to 86] 
79 [68 to 90] 
72 [65 to 79] 
77 [72 to 83] 
63 [57 to 69] 
80 [73 to 87] 
89 [82 to 96] 
81 [77 to 85] 
Petersen 2016 
(Germany) 
MMP & brace 
n = 78 
Age = 28 (9) 
BMI = 23 (2) 
W = 51% 
 
 Randomized trial 
comparing change in 
QOL following  
MMP 
& brace intervention 
vs. MMP alone 
6 weeks KOOS-QOL  40 [37 to 44] 69 [65 to 72] 
  
MMP 
n = 78 
Age = 28 (8) 
   
6 weeks 
   
43 [40 to 45] 
 
60 [55 to 65] 
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BMI = 23 (1) 
W = 61% 
Study PFP 
 
Control 
 
Comparison or 
Intervention 
Rx 
Duration 
QOL 
measures 
Domain PFP Comparator 
 
Rathleff MS 2014 
(Denmark) 
Physiotherapy + 
Education 
n = 62 
Age = 17 (1) 
BMI = 21 (3) 
W = 74% 
 
Education 
 Cluster randomized 
trial comparing change 
in QOL following 
supervised 
physiotherapy + 
education vs. education 
alone 
12 weeks KOOS-QOL  57 [52 to 61]     62 [54 to 71] 
 n = 59 
Age = 17 (1) 
BMI = 22 (3) 
W = 86% 
  12 weeks   53 [49 to 57]  54 [52 to 57] 
Syme 2011 
(UK) 
VMO training 
n = 23 
Age = 29 (8) 
BMI = 26 (1) 
W = 57% 
 
 Randomized controlled 
trial comparing change 
in QOL following 
vastus medialis oblique 
selective training vs. 
general quadriceps 
strengthening 
 
8 weeks SF-36  PCS 
MCS 
45 [42 to 48] 
45 [42 to 48] 
  
53 [49 to 58] 
46 [42 to 51] 
 Quadriceps 
strengthening 
n = 23 
Age = 27 (8) 
BMI = 26 (1) 
W = 57% 
 
  8 weeks  PCS 
MCS 
47 [43 to 50] 
47 [43 to 50] 
 
54 [49 to 60] 
50 [47 to 54] 
  No treatment 
n = 23 
 8 weeks  PCS 
MCS 
47 [43 to 50] 
47 [43 to 50] 
40 [32 to 48] 
49 [44 to 54] 
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Age = 29 (6) 
BMI = 26 (1) 
W = 65%  
Study PFP 
 
Control 
 
Comparison or 
Intervention 
Rx 
Duration 
QOL 
measures 
Domain PFP Comparator 
 
Repeated measure intervention studies 
Akkurt 2010 
(Turkey) 
n = 22 
Age = 35 (8) 
BMI = NR  
W = 100% 
 Repeated measures 
study of QOL 
following isokinetic 
exercise 
6 weeks SF-36  
 
PCS 
MCS 
40 [31 to 49] 
51 [41 to 60] 
63 [55 to 72] 
67 [59 to 75] 
Banan 2016 
(Iran) 
n = 25 
Age = 35 (10) 
BMI = 25 (7)  
W = 80% 
 Repeated measures 
study of QOL 
following rigid taping 
4 weeks KOOS-QOL 
 
 12 [8 to 15] 13 [9 to 17] 
Eapen 2011 
(India) 
n = 20 
Age = 28 (7) 
BMI = NR  
W = 60% 
 Repeated measures 
study of QOL 
following eccentric 
exercise 
2 weeks 
 
SF-36 
 
BP 
PCS 
MCS 
 
45 [40 to 51] 
37 [35 to 39] 
42 [39 to 45] 
75 [69 to 80] 
48 [46 to 49] 
44 [43 to 46] 
Haim 2013 
(Israel) 
n = 48 
Age = 31 (7) 
BMI = 24  
W = 44% 
 
 Repeated measures 
study of QOL 
following use of 
biomechanical device 
in shoe 
26 weeks SF-36 
 
PF 
RP 
BP 
GH 
V 
SF 
RE 
MH 
PCS 
MCS 
61 [55 to 66] 
42 [30 to 53] 
51 [44 to 57] 
60 [55 to 66] 
50 [44 to 56] 
76 [69 to 83] 
69 [57 to 82] 
68 [64 to 73] 
53 [47 to 58] 
65 [59 to 71] 
64 [58 to 70] 
54 [43 to 65] 
58 [53 to 64] 
65 [59 to 70] 
54 [48 to 59] 
81 [74 to 88] 
73 [61 to 85] 
68 [63 to 73] 
59 [54 to 64] 
68 [63 to 73] 
Kuru 2012 
(Turkey) 
Kinesio tape & 
exercise 
n = 15 
Age = 33 (12) 
BMI = 24 (5)  
 Repeated measures 
study of QOL 
following Kinesio tape 
& exercise vs. 
Electrical stimulation 
6 weeks 
 
SF-36 
 
PF 
RP 
BP 
GH 
V 
41 [37 to 45] 
34 [29 to 39] 
40 [36 to 44]  
40 [36 to 45] 
46 [42 to 49] 
49 [45 to 52] 
45 [41 to 50] 
50 [47 to 53] 
44 [40 to 48] 
51 [47 to 54] 
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 182 
 183 
W = 80% 
 
 
+exercise SF 
RE 
MH 
42 [38 to 47] 
39 [32 to 47] 
40 [35 to 45] 
47 [44 to 50] 
50 [46 to 55] 
44 [41 to 47]  
Study PFP 
 
Control 
 
Comparison or 
Intervention 
Rx 
Duration 
QOL 
measures 
Domain PFP Comparator 
 
Kuru 2012 
(Turkey) 
(Continued) 
Electrical 
stimulation & 
exercise 
n = 15 
Age = 41 (11) 
BMI = 27 (4)  
W = 93% 
 
  6 weeks 
 
SF-36 
 
PF 
RP 
BP 
GH 
V 
SF 
RE 
MH 
39 [33 to 45] 
43 [35 to 50] 
43 [38 to 49] 
43 [37 to 49] 
44 [38 to 49] 
44 [39 to 49] 
43 [34 to 51] 
40 [33 to 46] 
48 [43 to 53] 
53 [49 to 57] 
52 [49 to 54] 
46 [41 to 51] 
48 [42 to 53] 
49 [44 to 54] 
53 [48 to 57] 
46 [41 to 50] 
Sinclair 2016 
(UK) 
n = 20 
Age = NR 
BMI = NR  
W = 45% 
 Repeated measures 
study of QOL 
following brace use 
2 weeks 
 
KOOS-QOL 
 
 53 [47 to 58] 68 [60 to 76] 
Tsai 2015 
(USA) 
n = 12 
Age = 39 (NR) 
BMI = 23 (NR) 
W = 75% 
 Repeated measures 
study of QOL 
following off-axis 
elliptical training 
6 weeks 
 
KOOS-QOL 
 
 49 [36 to 62] 61 [48 to 74] 
Note. Demographic data are presented as mean (standard deviation), unless otherwise stated. Quality of life data are presented as mean [95% confidence interval]. 
Abbreviations as follows: PFP, patellofemoral pain; Rx, treatment; QOL, quality of life; BMI, body mass index (kg/m2);  W, women; NR, not reported; KOOS, Knee Injury and
Osteoarthritis Outcome Score; SF-36, Short-Form 36-Item Health Survey; PF, physical function; RP, role physical; BP, bodily pain; GH, general health; V, vitality; SF-social 
function; RE, role emotional; MH, mental health; SF-8, Short-Form 8-Item Health Survey; MMP, multi-modal physiotherapy; * symbol denotes BMI not reported but estimated 
from height and mass; † is PFP participant data deriv d from participants included in largest cohort reported in 2014 paper 
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Eleven studies investigated the effect of a treatmen  intervention on QoL in PFP individuals. 184 
Interventions included single treatment and multi-modal physical therapy, shoe inserts, braces 185 
and elliptical training. The methodological quality scores ranged from 31-100%, with a 186 
median score of 67% (Table 2). There were 12 studies of higher quality and nine studies of 187 
lower quality. Of the four controlled intervention studies, there was one low risk of bias 188 
study, one unclear, and two high risk of bias studies (Table 3). 189 
 190 
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 TABLE 2. Reported methodological quality of the included studies. 191 
 Note. N/A is not applicable. Higher quality is median score (67%) or above and lower quality is below median (<67%) 192 
 193 
Author  1  2  3  5  6  7  10  11  12  15  18  20  25  26  27  Score Total %  Quality 
QOL in PFP (cross-section studies compared to control) 
Assa 2013 1  1  1  1  1  1 1 0 0 1 1  1 0  N/A  1  11 15 73 Higher 
Rathleff CR 2013 1  1  1  2 1  1 1  1  0  1  1  1  1  N/A  0  13 15 87 Higher 
Rathleff MS 2013 1  1  1  2  1   0 1  1  0 0 1  0  1  N/A  0 10 15 67 Higher 
Rathleff MS 2016 1 1 1 2 1 1 1 1 0 1 1 1 1 N/A 1 14 15 93 Higher 
QOL in PFP (cross-section & validity studies) 
Apivatgaroon 2016 1  1  1  N/A 1  1 N/A 0 0 N/A N/A 1  N/A N/A N/A 6 8 75 Higher 
Cheung 2012 1  1  1  N/A  1  0  N/A   0  0 N/A  N/A  1  N/A  N/A  N/A  5 8 63 Lower 
Cheung 2013 1  1  1  2  1  1  1  0 0 0  0  1  1 N/A  1  11 15 73 Higher 
Negahban 2013 1 1 1 N/A  1 1  N/A   0  0 N/A  N/A  1 N/A  N/A  N/A  6 8 75 Higher 
Silva 2016 1  1  1  2  1  1  1  1 0 0 1  1  1  N/A  1  13 15 87 Higher 
Vincent 2010 1  1  0  2   1   0 1  0   0  0 1  1  1  N/A  1  10 15 67 Higher 
Effect of intervention on QOL for PFP (randomised controlled studies) 
Crossley 2002 1  1  1  2  1  1  1  1  0 1  1  1  1  1 1  15 16 94 Higher 
Petersen 2016 1  1  1  1 1  0  0 1   0 0  1  1  1  0 1  10 16 63 Lower 
Rathleff 2014 1  1  1  2 1  1   0 1  1  1  1  1  1  1 1  15 16 94 Higher 
Syme 2009 1 1 1 2  1 1  0 1 1  1  1 1 1 1 1 15 16 94 Higher 
Effect of intervention on QOL for PFP (repeated measures studies) 
Akkurt 2010 1  1  1  0  1  1  1  0 0 0  0 0 0 0 0 6 16 38 Lower 
Banan 2016 1  1  1  1  1  1  1   0  0  0 0 1  0 0 0 8 16 50 Lower 
Eapen 2011 1  1  1   0 1  1  1  0 0 0 1  0 0 0 1  8 16 50 Lower 
Haim 2013 1 1 1 1  1 1 1  0  0  0 1  0 0 N/A 1  9 15 60 Lower 
Kuru 2012 1  1  1 1 1  1  1  0 0 0  0 0 0 1  0  8 16 50 Lower 
Sinclair 2016 1  1   0  0 1  1  0   0  0  0 1  0 0 0 0 5 16 31 Lower 
Tsai 2015 1  1  0 0 1  1   0 0 0 0 1  0 0 1  1 7 16 44 Lower 
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TABLE 3: Risk of bias of included controlled intervention studies. 194 
 195 
Low risk of bias (bias if present is unlikely to alter he results seriously);  196 
Unclear risk of bias (a risk of bias that raises some doubt about the results);  197 
High risk of bias (bias may alter the results seriously) 198 
 199 
 200 
 201 
 202 
 203 
 204 
 205 
 206 
 207 
 208 
 209 
Study Random 
sequence 
generation 
Allocation 
concealment 
Blinding of 
participants & 
personnel 
Blinding of 
outcome 
assessment 
Incomplete 
outcome data 
Selective 
reporting 
Other bias Risk of bias 
within trial 
Crossley 2002 Low Low Low Low Low Low Low Low risk 
Petersen 2016 High High High High Unclear Unclear High High risk 
Rathleff 2014 Low Low Unclear Low Low Low Low Unclear risk 
Syme 2009 Low Low High Low Low Low High High risk 
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3.3 QoL in Individuals with PFP 210 
Knee-related QoL in individuals with PFP 211 
Seven studies reported knee-related QoL (KOOS-QoL) in individuals with PFP.6,34,36,41,47,48,51 212 
The pooled mean KOOS-QoL score from 7 studies (3 higher quality and 4 lower quality) in 213 
individuals with PFP was 47 [95% CI: 34 to 61] (Figure 2).  214 
 215 
 216 
One study considered an outlier (i.e. mean KOOS-QoL score (11) was outside the 95% CI for 217 
the pooled mean),6 when excluded from the analysis, resulted in a pooled mean KOOS-QoL 218 
score of 53 [95% CI: 45 to 61]. A single study reported knee-related QoL in athletes with 219 
PFP (KOOS-QoL score, 78 [95% CI: 70 to 86]) (Table 4).47 220 
 221 
 222 
 223 
 224 
 225 
 226 
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TABLE 4. Quality of life in athletes with PFP compared to active population norms. 227 
 
Included studies 
Active 
Population 
Norm  
Mean difference 
PFP-Pooled 
 
Silva 2016 
PFP-Athletes 
Cameron 
2013 
 
PFP Athletes v Active Norm 
 
KOOS-
QoL 
47 [34 to 61] 78 [70 to 86] 92 (12) 14 
 
     
SF-36 PFP-Pooled 
 
Cheung 2013 Huffman 
2008 
 
Mean difference 
 
 PFP-
Amateur 
athletes 
PFP-
Professional 
athletes 
 PFP 
Amateur 
athletes v 
Active Norm 
PFP 
Professional 
athletes v 
Active Norm 
PF 59 [45 to 74] 88 [80 to 96] 75 [67 to 82] 99 [98 to 100] 11 24 
RP 50 (41 to 60] 78 [59 to 96] 42 [23 to 62] 96 [94 to 98] 18 54 
BP 49 [45 to 53] 63 [54 to72] 51 [41 to 62] 89 [87 to 91] 26 38 
GH 57  [50 to 66] 66 [56 to 76] 65 [56 to 74] 86 [85 to 88] 20 21 
V 54 [49 to 58] 63 [55 to72] 55 [44 to 65] 71 [69 to 73] 8 16 
SF 67 [55 to 79] 83 [72 to 93] 78 [71 to 86] 96 [95 to 98] 13 18 
RE 61 [50 to 73] 67 [45 to 88] 58 [37 to 79] 98 [97 to 99] 31 40 
MH 64 [55 to 72] 74 [66 to 80] 65 [58 to 71] 83 [82 to 85] 9 18 
 228 
All data reported as mean, [95%CI]. 229 
Active population norm reported in groups with no history of injury 230 
 231 
Knee-related QoL in individuals with PFP compared to population norms 232 
The previously reported mean KOOS-QoL score from a general population sample of young 233 
adults was 84 [95% CI: 81 to 88]33. Based on the pooled scores, individuals with PFP had 234 
worse knee-related QoL relative to this general population sample (mean difference: 37; 235 
[KOOS-QOL 95% CI: 34 to 61]). The previously published mean KOOS-QoL score from 236 
active individuals (with no history of knee injury) was 92 [95% CI: 92 to 93].9 Based on this 237 
data, athletes with PFP had worse knee-related QoL relative to norms from an active 238 
population (mean difference: 14; [KOOS-QOL 95% CI: 70 to 86]). 239 
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 240 
Knee-related QoL in individuals with PFP compared to pain-free controls 241 
Three included studies36,39,42 provided KOOS-QoL data from three different groups of pain-242 
free individuals (i.e. 69 females) and the pooled mean KOOS-QoL score was 98 [95% CI: 97 243 
to 100]. Based on the pooled scores, individuals with PFP had worse knee-related QoL 244 
relative to pain-free controls (mean difference: 51). 245 
 246 
Health-related QoL in individuals with PFP 247 
Fourteen studies reported health-related QoL in indiv duals with PFP using SF-36, SF-8, and 248 
EQ-5D measures. Eleven studies reported on QoL using the SF-36; eight of these studies 249 
reported SF-36 domain scores,4,5,11,12,14,20,27,32 seven studies reported SF-36 summary 250 
scores2,4,5,16,20,32,49 and four reported both domain and summary scores.4,5,20,32 One paper used 251 
the SF-857 and two studies used the EQ-5D36,41 (one study used a youth version (EQ-5D-Y)).36 252 
 253 
Pooled SF-36 domain scores from 7 studies (4 higher quality4,5,14,32 and 3 lower quality11,20,27) 254 
in individuals with PFP were: physical function 59 [95% CI: 45 to 74], role physical 50 [95% 255 
CI: 41 to 60], bodily pain 49 [95% CI: 45 to 53], general health 57 [95% CI: 50 to 66], 256 
vitality 54 [95% CI: 49 to 58], social function 67 [95% CI: 55 to 79], role emotional 61 [95% 257 
CI: 50 to 73] and mental health 64 [95% CI: 55 to 72]. A single study reported health-related 258 
QoL (SF-36 domains) in amateur and professional athletes with PFP12 (Table 4). Pooled SF-259 
36 PCS and MCS scores from 7 studies (4 higher quality4,5,32,49 and 3 lower quality2,16,20) 260 
were 47 [95% CI: 41 to 53] and 54 [95% CI: 47 to 62] respectively. 261 
 262 
A PFP subgroup from a single study57 of individuals with knee pain-related diagnoses 263 
reported health-related QoL measured with SF-8 (physical function 49 [95% CI: 46 to 52], 264 
role physical 39 [95% CI: 36 to 42], bodily pain 35[95% CI: 30 to 39], general health 43 265 
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[95% CI: 41 to 46], vitality 51 [95% CI: 48 to 53], social function 46 [95% CI: 43 to 49], role 266 
emotional 51 [95% CI: 49 to 54] and mental health 48 [95% CI: 46 to 51]). 267 
 268 
Two studies reported health-related QoL in individuals with PFP measured with EQ-5D,36,41 269 
but were unable to be pooled as they used different v rsions of the EQ-5D and one study36 270 
reported median score rather than mean. Scores fromthese 2 studies were mean 0.75 271 
[standard deviation (SD)=0.12]41 and median 0.72 [interquartile range 0.68-0.78].36 272 
 273 
Health-related QoL in indiviudals with PFP compared to population norms 274 
Relative to previously reported mean SF-36 domain scores from a general population 275 
sample,29 individuals with PFP had worse health-related QoL (mean difference: physical 276 
function=34, role physical=36, bodily pain=30, general health=24, vitality=6, social 277 
function=20, role emotional=23 and mental health=14). Additionally, amateur and 278 
professional athletes with PFP from a single study, also had worse health-related QoL when 279 
compared to previously published SF-36 scores from an active general population sample 280 
(Table 4).23 281 
 282 
Health-related QoL in individuals with PFP compared to pain-free controls 283 
Compared to mean SF-36 domain scores in pain-free controls,5 individuals with PFP had 284 
worse health-related QoL (mean difference: physical function=38, role physical=47, bodily 285 
pain=43, general health=25, vitality=18, social function=30, role emotional=37 and mental 286 
health=16) (Figure 3). 287 
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 288 
 289 
Individuals with PFP also had worse health-related QoL based on SF-36 PCS and MCS when 290 
compared to data from pain-free controls5 (mean difference: PCS=41, MCS=32) (Table 1). 291 
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Only one study reported EQ-5D scores in individuals with PFP (median score: 0.72) 292 
compared to pain-free controls (median score: 1.00).36 293 
 294 
3.4 Effects of PFP Intervention on QoL  295 
Knee-related QoL 296 
Two RCTs reported conflicting evidence for the effect of intervention on KOOS-QoL.34,41 A 297 
lower-quality and high risk of bias study showed that the combined treatment of a knee brace 298 
and multi-modal physical therapy, compared to multi-modal physical therapy alone 299 
significantly improved knee-related QoL (SMD=0.45 [95% CI: 0.13 to 0.77]).34 A higher-300 
quality and unclear risk of bias study reported no statistically significant differences in knee-301 
related QoL between individuals with PFP receiving physical-therapist supervised 302 
neuromuscular retraining and home exercise with an education session, and those receiving 303 
an education session alone (SMD=0.31 [95% CI: -0.05 to 0.67]) (Figure 4).41  304 
 305 
 306 
 307 
Pooled data from three lower-quality repeated measur s design studies6,48,51 provided limited 308 
evidence of moderate improvement in knee-related QoL p st-intervention (interventions 309 
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consisted of brace, off-axis elliptical trainer and tape) compared to pre-intervention 310 
(SMD=0.54 [95% CI: 0.04 to 1.04], I2=41%, p=0.03) (Figure 5). 311 
 312 
 313 
 314 
Health-related QoL 315 
Two RCTs reported conflicting evidence of the effect of intervention on SF-36 scores.14,49 A 316 
higher-quality and low risk of bias study investigaed the effect of multi-modal physical 317 
therapy compared to a placebo intervention and found no significant differences between the 318 
domain scores of the two groups (Tables 1 and 2).14 Another higher-quality but high risk of 319 
bias study investigated the effects of two multi-modal physical therapy treatments; one based 320 
on McConnell taping and selective vastus medialis obliquus exercise (VMO), and the other 321 
comprised of sling taping and quadriceps strengthening.49 QoL outcomes were compared to a 322 
(no treatment) control group. Large improvements were observed following analysis of 323 
combined mean PCS scores following multi-modal physical therapy for all treated 324 
individuals (SMD=0.93 [95% CI: 0.41 to 1.46]) relative to the control group. There was no 325 
significant difference in PCS or MCS scores between intervention groups. Large PCS score 326 
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improvements were observed following analysis of each intervention group compared to no 327 
intervention; McConnell taping plus VMO exercise group (SMD=0.84 [95% CI: 0.23 to 328 
1.44]) and the sling taping plus quadriceps strengthening group (SMD=0.87 [95% CI: 0.26 to 329 
1.48]) (Figure 4).49  330 
 331 
Four repeated measures design studies reported health-r l ted QoL pre- and post- 332 
intervention.2,16,20,27 Pooled SF-36 summary scores from three lower-quality studies2,16,20 333 
provided limited evidence of large improvements in health-related QoL (PCS SMD=1.36 334 
[95% CI: 0.19 to 2.54], I2=92%, p=0.02, MCS SMD=0.46 [95% CI: 0.06 to 0.85], I2=46%, 335 
p=0.02) post-intervention (strengthening, biomechanical foot-worn device) relative to pre-336 
intervention (Figure 5). A lower-quality study investigated two intervention for PFP: (i) 337 
Kinesio taping plus exercise program, and (ii) electrical stimulation of VMO plus exercise 338 
program.27 Compared to pre-intervention, both interventions resulted in significant 339 
improvements in SF-36 domain scores, except for vitality.27 340 
 341 
3.5 Factors associated with QoL in Individuals with PFP 342 
Due to the very limited number of controlled studies, random effects meta-analysis to 343 
determine factors related to QoL outcomes in individuals with PFP could not be performed. 344 
 345 
4.0 DISCUSSION  346 
4.1 QoL in Individuals with PFP 347 
This systematic review revealed that individuals with PFP had substantially worse knee- and 348 
health-related QoL relative to pain-free controls (KOOS-QoL mean difference: 51, SF-36 349 
domains mean difference range: 16-47) and population norms (KOOS-QoL mean difference: 350 
37, SF-36 domains mean difference range: 14-36). Impair ents in knee- and health-related 351 
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QoL, were highlighted by the fact that pooled PFP mean 95% CI upper limits were all lower 352 
than the 95% CI lower limits for pain-free and normative QoL group means. Impairments in 353 
SF-36 PCS scores in individuals with PFP compared to the reference group, were greater than 354 
MCS scores, suggesting an emphasis on addressing physical impairments is needed to 355 
improve QoL in individuals with PFP. 356 
 357 
Recent systematic reviews indicate similar impairments in KOOS-QoL for a range of other 358 
knee conditions, including knee osteoarthritis (pooled mean=35)13, anterior cruciate ligament 359 
(ACL) injury (pooled mean=44)13, and 5-16 years following ACL reconstruction (pooled 360 
mean=74)17. Our findings indicate that the impact of PFP (pooled mean=47) on knee-related 361 
QoL approaches that of knee osteoarthritis. Additionally, knee-related QoL impairment in 362 
people with PFP is similar or greater than QoL impairment following ACL injury, which is 363 
considered to be a life-changing event with substantial physical and psychological 364 
impacts.25,43 365 
 366 
Our findings indicate athletetic cohorts with PFP (e.g. KOOS-QoL = 78)12,47 have better 367 
knee- and health-related QoL compared to pooled findings of PFP cohorts without inclusion 368 
based on athletic status (e.g. KOOS-QoL = 47). This finding is not surprising considering 369 
athletes generally have an increased perception of their health in comparison with age-370 
matched peers.9,23,47 However, when compared to QoL norms measured in act ve populations, 371 
our findings indicate both knee- and health-related QoL was impaired in athletes with PFP. 372 
 373 
4.2 Effects of PFP Intervention on QoL 374 
Findings from repeated measure intervention studies indicate that knee- and health-related 375 
QoL improved following interventions for PFP including bracing, taping and exercise 376 
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therapy. Importantly, these improvements are greate than the minimal clinically important 377 
improvement (MCII) reported for KOOS-QoL (8-10 points)44 and the SF-36 PCS and MCS 378 
(5-7 points).60,61 However, less improvement was observed in SF-36 MCS scores (mean 379 
difference improvement: 6 points), perhaps reflecting the greater impairment in PCS 380 
compared with MCS at baseline. Significant improvements in knee- and health- related QoL 381 
following intervention in these repeated measure studies should be interpreted with caution. 382 
Importantly, a lack of control or comparison group means it is unclear if these improvements 383 
were the result of the intervention, placebo, physical-therapist interaction, natural history, or a 384 
combination of these factors.53 Unfortunately, there are currently very few RCTs to provide 385 
further insight. 386 
 387 
Very limited evidence from one RCT, indicated that despite significant improvements in pain 388 
and function, knee-related QoL did not improve more following physical-therapy 389 
intervention (i.e., patellofemoral soft tissue mobilisation, strength exercises, neuromuscular 390 
training) plus education in comparison to education alone. It is possible that the KOOS-QoL 391 
subscale (assessing lifestyle modification, knee awareness, knee confidence and knee 392 
difficulties) may not be sensitive to changes in knee pain and function. Similarly, two RCTs 393 
reported significant improvements in pain and function for individuals that received multi-394 
modal physical therapy compared to controls, but the impact of intervention on health-related 395 
QoL was conflicting. Physical interventions may need to be specifically developed in order to 396 
target improvements in knee- and health-related QoL. Further research is needed to determine 397 
the most effective interventions for improving QoL in individuals with PFP. 398 
 399 
Interestingly, Rathleff et al 2014, was the only RCT to encourage ongoing self management 400 
and exercise in the longer term (i.e. 12 months) and was also the only controlled study 401 
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without a high risk of bias to report significant improvements in knee-related QoL at longer-402 
term follow up (i.e. 12 months), specifically in adolescents. This may indicate that improving 403 
QoL in individuals with PFP requires longer-term physical interventions and follow up (e.g. 404 
beyond the common 6-12 week clinical trial period), although further research is needed to 405 
confirm this, particularly in adults.  406 
 407 
4.3 Limitations and Recommendations for Future Research 408 
Firstly, all relevant studies were included regardless of methodological quality due to the 409 
paucity of research in this area. Therefore, low-quality studies may bias the findings. To 410 
account for this, the levels of evidence reported in th s review involve consideration of study 411 
homogeneity, quality and quantity. 412 
 413 
Previously published normative QoL data from Norway29 and Sweden33 were used for 414 
comparison as these were the largest published normative samples. However the comparison 415 
between Scandinavian normative QoL data and pooled QoL data from individuals with PFP 416 
from many different countries, may have biased these results.1 Although chronic 417 
musculoskeletal conditions have been shown to have a similar impact on health-related QoL 418 
measured by the SF-36 in eight (Western) countries3, comparison with non-Western cultures 419 
is complex52 and such analysis is beyond the scope of this review. 420 
 421 
Pain-free control group QoL data was very limited (i.e., 4 studies) which may bias pooled 422 
mean knee- and health-related QoL comparisons against individuals with PFP. Additionally, 423 
three of the four control groups were comprised of adolescent and adult women and lower 424 
health-related QoL scores have been reported in women compared to men.10,26 However, due 425 
to the small number of included studies reporting QoL data for men and women, sex-based 426 
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analyses were not conducted. Given sex-based differenc s associated with PFP, future 427 
research should consider reporting data for men and women separately. 428 
 429 
Most intervention studies included in this systematic review measured knee- or health-related 430 
QoL as a secondary outcome, and hence may be underpowered to detect changes in QoL.59 431 
Considering we found markedly impaired QoL in indivi uals with PFP, future research 432 
should consider QoL measures as a primary intervention target and power participant 433 
recruitment accordingly. We were unable to determine whether other participant or 434 
methodological factors are associated with QoL in individuals with PFP, due to the small 435 
number of controlled studies published. 436 
 437 
5.0 CONCLUSION 438 
Individuals with PFP aged under 50 years, have impaired knee- and health-related QoL 439 
compared to the general population and pain-free individuals. Based on current evidence, 440 
including a paucity of high quality randomised contr lled trials, it is unclear whether 441 
common interventions provided to individuals with PFP have any beneficial effect on knee- 442 
and health-related QoL when compared to a control group. Developing treatments to target 443 
knee-related and health-realted QoL in individuals with PFP and evaluating their efficacy in 444 
longer-term, high-quality randomized controlled trials is urgently needed. 445 
 446 
 447 
 448 
 449 
 450 
 451 
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APPENDIX 1: Search Strategy for MEDLINE 
CONCEPT KEYWORDS MESH HEADING  
Patellofemoral 
pain 
    1. anterior knee pain.mp. 
2. patella* or femoropatell* or retropatell* or patellofemoral or   
patello-femoral adj2 pain or syndrome or dysfunction.mp 
3. lateral compression or lateral facet or lateral p essure or odd facet 
adj2 syndrome.mp 
4. chondromalac* or chondropath* or chondrosis adj2 patell* or 
femoropatell* or retropatell* or femoro-patell*.mp. 
5. Patella/ or Knee joint/ or Knee/ AND Pain/ or 
Arthralgia/ 
6. Patellofemoral pain syndrome/ 
7. Chondromalacia Patellae/ 
 
 
 
  8.   OR/1-7 
Quality of life 9. Knee Injury and Osteoarthritis Outcome Score or KOOS.mp. 14. Quality of life/  
10. Short?form 36 OR SF?36 OR Short?form 12 OR SF?12 OR Short 
Form Health Survey.mp. 
  
11. EQ5D OR EQ-5D*.mp. 
12. QOL OR AQOL OR Health related quality of life or HRQOL.mp. 
13. lower extremity activity profile or leap.mp 
  
 
15.   OR/9-14 
   16. 8. AND 15. 
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APPENDIX 2. Modified Downs & Black checklist for methodological quality appraisal. 
 
Note. N/A is not applicable 
Item Title Description by Downs& Black Yes No/Unable 
to 
determine 
Partially Inter-
vention 
Cross-
section 
Validity 
1 Aim Is the hypothesis/aim/objective clearly described? 1 0     
2 Outcomes 
Are the main outcomes to be measured clearly described in the 
Introduction or Methods section? 
1 0     
3 Participants 
Are the characteristics of the patients included in the study clearly 
described? 
1 0     
5 Confounders 
Are distributions of principal confounders in each group of subjects to 
be compared clearly described? 
2 0 1   N/A 
6 Findings Are the main findings of the study clearly described? 1 0     
7 
Random 
variability 
Does the study provide estimates of the random variability in the data 
for the main outcomes 
1 0     
10 Probability 
Have actual probability values been reported for the main outcomes 
except where the probability value in less than 0.001? 
1 0    N/A 
11 External validity 
Were the subjects asked to participate in the study representative of the 
entire population from which they were recruited? 
1 0     
12 External validity 
Were those subjects who were prepared to participate representative of 
the entire population from which they were recruited? 
1 0     
15 Blinding 
Was an attempt made to blind those measuring the main outcomes of 
the intervention? 
1 0    N/A 
18 Statistical tests Were the statistical tests used to assess the main outcomes appropriate? 1 0    N/A 
20 
Accurate 
outcomes 
Were the main outcome measures used accurate (validand reliable)? 1 0     
25 
Confounding 
adjustment 
Was there adequate adjustment for confounding in the analyses from 
which the main findings were drawn? 
1 0    N/A 
26 
Loss to follow-
up 
Were losses of patients to follow-up taken into account? 1 0   N/A N/A 
27 Power 
Did the study have sufficient power to detect a clini ally important 
effect where probability value for difference being due to chance is < 
5% 
1 0    N/A 
 Max score  16   16 15 8 
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HIGHLIGHTS 
People with patellofemoral pain have impaired quality of life  
Quality of life is worse than the general population  
Quality of life is worse than pain-free people  
Physical therapy may improve quality of life  
 
